Lisa J McGarry

Summary

Publications

  1. pmc Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States
    Lisa J McGarry
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    BMC Infect Dis 13:229. 2013
  2. doi Economic model of a birth cohort screening program for hepatitis C virus
    Lisa J McGarry
    OptumInsight, Medford, MA 02155, USA
    Hepatology 55:1344-55. 2012
  3. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
  4. pmc Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA
    BMC Infect Dis 10:14. 2010
  5. pmc Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission
    Lisa J McGarry
    OptumInsight, Cambridge, Massachusetts, United States of America
    PLoS ONE 9:e72723. 2014
  6. doi Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia
    Lisa J McGarry
    i3 Innovus, 10 Cabot Road, Medford, MA 02155, USA
    J Med Econ 13:142-7. 2010
  7. pmc Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
    Lisa J McGarry
    OptumInsight, Cambridge, Massachusetts, United States of America
    PLoS ONE 8:e67260. 2013
  8. ncbi Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients
    Lisa J McGarry
    Innovus Research Inc, Medford, Mass 02155, USA
    Am J Manag Care 10:632-42. 2004

Detail Information

Publications8

  1. pmc Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States
    Lisa J McGarry
    OptumInsight, One Main Street, Suite 1040, Cambridge, MA 02142, USA
    BMC Infect Dis 13:229. 2013
    ....
  2. doi Economic model of a birth cohort screening program for hepatitis C virus
    Lisa J McGarry
    OptumInsight, Medford, MA 02155, USA
    Hepatology 55:1344-55. 2012
    ..Conclusion: Birth-cohort screening for HCV is likely to provide important health benefits by reducing lifetime cases of advanced liver disease and HCV-related deaths and is cost-effective at conventional willingness-to-pay thresholds...
  3. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
    ..Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%...
  4. pmc Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic
    Jaime L Rubin
    i3 Innovus, 10 Cabot Road, Suite 304, Medford, MA 02155, USA
    BMC Infect Dis 10:14. 2010
    ..The 2009 novel influenza A (H1N1) outbreak highlights the importance of interventions that may mitigate the impact of a pandemic...
  5. pmc Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission
    Lisa J McGarry
    OptumInsight, Cambridge, Massachusetts, United States of America
    PLoS ONE 9:e72723. 2014
    ....
  6. doi Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia
    Lisa J McGarry
    i3 Innovus, 10 Cabot Road, Medford, MA 02155, USA
    J Med Econ 13:142-7. 2010
    ..This study compares the economic outcomes of IV therapy with doripenem versus imipenem as first-line treatment for VAP...
  7. pmc Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
    Lisa J McGarry
    OptumInsight, Cambridge, Massachusetts, United States of America
    PLoS ONE 8:e67260. 2013
    ....
  8. ncbi Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients
    Lisa J McGarry
    Innovus Research Inc, Medford, Mass 02155, USA
    Am J Manag Care 10:632-42. 2004
    ..To compare the cost effectiveness of prophylaxis with a low-molecular-weight heparin with that of prophylaxis with unfractionated heparin for the prevention of venous thromboembolism in acutely ill medical inpatients...